News Archives | Wasdell Group

Wasdell Sponsor Swindon & Wiltshire, Health & Social Care Awards

March 24, 2021 / by Wasdell Group /

Direct-to-patient services in practice: COVID 19 case studies

September 7, 2020 / by Wasdell Group /

The Covid 19 pandemic has placed additional emphasis on the healthcare industry shift towards more patient-centric approaches, particularly with clinical trials. Increasingly, services such as Direct-to-Patient (DtP) and Direct-from-Patient (DfP) shipment approaches are now being viewed as critical. Delivering Investigational Medicinal Product (IMP) to patients participating in clinical trials requires the establishment of a framework […]

The rise of direct-to-patient services

September 7, 2020 / by Wasdell Group /

The COVID-19 pandemic has significantly disrupted clinical trials, yet the industry is adapting and finding opportunities and new ways to serve patients. Logistical challenges, including the inability of patients to attend clinics has placed added emphasis on Direct-to-Patient (DtP) services. So, in the current climate why should DtP clinical trial material shipments be integrated into […]

Wasdell makes multi-million-pound investment in new packaging equipment

May 6, 2020 / by Wasdell Group /

Leading pharmaceutical outsourcing partner, the Wasdell Group (Wasdell), has announced a multi-million-pound investment in new packaging equipment across its sites in the UK. The company, which specialises in end-to-end supply chain services, made the decision to invest in line with increasing demand for its manufacturing & packaging capabilities from its growing pharma and biotech client […]

Wasdell acquires specialist packaging supplier

April 23, 2020 / by Wasdell Group /

The Wasdell Group, a leading outsourcing partner to the pharmaceutical industry, has announced its acquisition of Planned Packaging Limited & Planned Packaging Films Limited (PPF), a specialist packaging supplier to the medical device and pharmaceutical sectors. The acquisition will strengthen and expand Wasdell’s capability to be a fully integrated supplier to its growing client base […]

COVID-19: A statement from our CEO

March 20, 2020 / by Wasdell Group /

The Wasdell Group want to update you on the current actions being taken to navigate the spread of COVID-19. Above all, we want to reassure our employees, customers and community that we are taking proactive action to maintain safety and minimise impact on our supply chains throughout this difficult time. Our operations continue to run […]

Wasdell Group extends business into the US

March 14, 2019 / by Wasdell Group /

We are delighted to announce that this year the Wasdell Group has recently established a presence within the United States, with a new US entity secured in Pennsylvania. The US presence comes as part of Wasdell’s latest step in extending our global reach to support our business activity and establish a local presence for our […]

Implications of Brexit on the FMD

February 8, 2019 / by Wasdell Group /

With still so much uncertainty around Brexit and it’s impact on the pharmaceutical industry, our Managing Director, Daniel Tedham talks to CPHI online about the possible implications of a ‘no-deal’ Brexit and what Wasdell are doing in a bid to ensure seamless operations. Read the full article […]

Wasdell expand with appointment of new CEO

January 23, 2019 / by Wasdell Group /

Wasdell are delighted to announce the appointment of our new C.E.O. Vincent Dunne who has joined us to further strengthen our service offerings to our customers and support the ongoing growth plans for the business. Read all about the Group’s new C.E.O. here: Wasdell Group appoints new CEO

Predictions for 2019

January 11, 2019 / by Wasdell Group /

With 2019 underway, Wasdell’s Managing Director Daniel Tedham weighs in with Pharma Manufacturing about the expectations for the next twelve months and what changes are to come. “As the demand for personalised medicines rises, smaller volume biotech products are therefore likely to be prevalent across 2019 as breakthroughs for rare and hard to treat conditions […]

1 2 3